Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Didem Torumkuney und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Unit, GSK, London, UK. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Haemophilus influenzae, Streptococcus pneumoniae, Drug Resistance, Bacterial. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK, Ashfield MedComms, Inizio company.
Abstract (Originalsprache)
Objectives
Antibiotic susceptibility determination of community-acquired respiratory tract infection (CA-RTI) isolates of Streptococcus pneumoniae and Haemophilus influenzae were collected from India (2018–21).
Methods
MICs were determined by CLSI broth microdilution; susceptibility data were interpreted using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
Results
S. pneumoniae (n = 177) and H. influenzae (n = 171) isolates were collected from four hospital laboratories and two private laboratories in India. Only 41.2% pneumococci were penicillin susceptible by CLSI oral/EUCAST low-dose breakpoints, but 94.4% were susceptible by EUCAST high-dose/CLSI IV breakpoints. Good activity (≥89.8%, CLSI or PK/PD breakpoints) was observed for amoxicillin, amoxicillin/clavulanic acid, cefotaxime, ceftriaxone, levofloxacin, and moxifloxacin. Cefdinir and second-generation cephalosporins were less active (27.7%–64.4%). Tetracyclines, macrolides and trimethoprim/sulfamethoxazole showed poor activity (18.6%–31.1%). EUCAST breakpoints indicated >90% susceptibility to high-dose ceftriaxone and penicillin, moxifloxacin and high-dose levofloxacin. Lower susceptibility to other cephalosporins and aminopenicillins was observed with EUCAST versus CLSI or PK/PD breakpoints. Most H. influenzae isolates (91.8%) were β-lactamase negative; 13 and 5 were β-lactamase-negative ampicillin-resistant following EUCAST and CLSI criteria, respectively. Antibiotic susceptibility was ≥84.8% (CLSI) for all antibiotics except trimethoprim/sulfamethoxazole (23.4%). Susceptibility by EUCAST was similar, except for cefuroxime (oral) with no susceptible isolates versus 95.3% by CLSI and ≤29.8% versus ≥85.4% for fluoroquinolones.
Conclusions
Some therapeutic options against S. pneumoniae and H. influenzae from CA-RTI in India remain, but only ceftriaxone covers both bacterial species using both guidelines. Continued surveillance of antibiotic susceptibility is important to monitor changes and trends in susceptibilities and for guiding empiric therapy of CA-RTIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Research Unit, GSK, London, UK.
- Department of Clinical Microbiology, Christian Medical College, Vellore, India.
- Microbiology and Infectious Molecular Biology, Metropolis Healthcare Private Limited, Vidyavihar West, Mumbai, India.
- Department of Microbiology and Division of Infectious Diseases, St John's Medical College Hospital, Bangalore, India.
- Department of Microbiology and Molecular Sciences, Toprani Advanced Lab Systems, Vadodara, India.
- Microbiology Research Center LTD, Peerless Hospital, Kolkata, India.
Förderung
- GSK
- Ashfield MedComms
- Inizio company
Zitieren
APA
Torumkuney, D., Veeraraghavan, B., Patil, N., Dias, M., Maheshwari, G., Chaudhuri, B. N., Ray, U., Hawser, S., Kundu, S., & Manoharan, A. (2025). Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf285
Vancouver
Torumkuney D, Veeraraghavan B, Patil N, Dias M, Maheshwari G, Chaudhuri BN, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf285
BibTeX
@article{Torumkuney2025,
author = {Torumkuney, Didem and Veeraraghavan, Balaji and Patil, Niranjan and Dias, Mary and Maheshwari, Geeti and Chaudhuri, Bhaskar Narayan and Ray, Ujjwayini and Hawser, Stephen and Kundu, Subhashri and Manoharan, Anand},
title = {Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf285}
}
EUVIMED